Moscarella E, et al. - In this subgroup analysis of the ULISSE registry, researchers compared the outcomes of the Ultimaster biodegradable polymer sirolimus-eluting stent (BP-SES) in a cohort of acute myocardial infarction (AMI) patients vs patients presenting without AMI (non-AMI). The incidence of 1-year target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction, and clinically indicated target lesion revascularization were assessed as the primary end point. An increased rate of TLF and definite stent thrombosis were observed in relation to Ultimaster BP-SES implantation in AMI patients vs non-AMI patients. The main driver of the high incidence of adverse events was the unfavorable baseline risk profile. Patients with AMI were more often female and smokers and had lower left ventricular ejection fraction and chronic kidney disease requiring dialysis vs non-AMI patients.